---
title: "Rigel Pharmaceuticals, Inc. (RIGL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RIGL.US.md"
symbol: "RIGL.US"
name: "Rigel Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T09:37:09.468Z"
locales:
  - [en](https://longbridge.com/en/quote/RIGL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RIGL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RIGL.US.md)
---

# Rigel Pharmaceuticals, Inc. (RIGL.US)

## Company Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.rigel.com](https://www.rigel.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: A
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: A (0.17)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 3 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: A

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 47.61% |  |
| Net Profit YoY | 879.70% |  |
| P/B Ratio | 1.31 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 523608864.00 |  |
| Revenue | 299767000.00 |  |

#### Multi Score Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 174.08% | A |
| Profit Margin | 121.51% | A |
| Gross Margin | 72.32% | A |
| Revenue YoY | 47.61% | A |
| Net Profit YoY | 879.70% | A |
| Total Assets YoY | 186.75% | A |
| Net Assets YoY | 2053.81% | A |
| Cash Flow Margin | 21.76% | D |
| OCF YoY | 47.61% | A |
| Turnover | 0.88 | B |
| Gearing Ratio | 20.75% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Rigel Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "47.61%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "879.70%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.31",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "523608864.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "299767000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "174.08%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "121.51%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "72.32%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "47.61%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "879.70%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "186.75%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "2053.81%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "21.76%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "47.61%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.88",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "20.75%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 1.44 | 9/386 | 8.97 | 6.24 | 1.63 |
| PB | 1.31 | 125/386 | 17.95 | 6.48 | 1.52 |
| PS (TTM) | 1.75 | 44/386 | 2.63 | 2.00 | 1.73 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 60% |
| Hold | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 28.30 |
| Highest Target | 71.00 |
| Lowest Target | 38.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RIGL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RIGL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RIGL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RIGL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**